Change in tumor size during cycle 1 (evaluable patients). Patients were evaluable if they had received study drug for at least 1 week at target dose or if study drug was stopped earlier because of progressive disease. One patient with tumor response was not evaluable per definition. “Missing” tumor size: progressive disease was assessed via clinical assessment alone in 2 patients, and 1 patient had nonmeasurable tumor at start of treatment. One patient with confirmed triple-hit lymphoma (3 gene rearrangements: c-MYC, BCL-2, and BCL-6) achieved a complete response. ● indicates patients who had previous autologous hematologic stem cell transplantation; Δ, patients with bulky disease (diameter >7.5 cm) at baseline; and ○, patients with transformed disease at baseline. PD, progressive disease; SD, stable disease.